Replies to post #146669 on Avid Bioservices Inc (CDMO)

[biopharm]

I just imagine a huge round table where the BP reps sit around discussing the major changes in biotech and each one wanting ...errr...rather needing the anti-PS platform to lock up their immunotherapy angle....

I think the only piece thats missing is the politicians. Big Pharma can sit at the round table but eventually they need the approval of someone higher....politically speaking.

Since the amendment filing mentioned Abbott as the partner last year I just wonder how their politics played into the misfortune of Black Monday. One such person... well, oncologist-- is Dr. Ezekiel J. Emanuel affiliated with Wharton @Univ. of Penn. and he actually had some ties to the Whitehouse for decision making in previous years and I though

http://en.wikipedia.org/wiki/Ezekiel_Emanuel

----------------------------------------------------

Diane v.S. Levy and Robert M. Levy University Professor

Professor of Health Care Management

Professor of Medical Ethics and Health Policy in the Perelman School of Medicine

Ezekiel J. Emanuel is Vice Provost for Global Initiatives and chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania. From January 2009 to January 2011, he served as special advisor for health policy to the director of the White House Office of Management and Budget. Since 1997 he was chair of the Department of Bioethics at The Clinical Center of the National Institutes of Health and a breast oncologist. Dr. Emanuel received his M.D. from Harvard Medical School and his Ph.D. in political philosophy from Harvard University. After completing his internship and residency in internal medicine at Boston's Beth Israel Hospital and his oncology fellowship at the Dana-Farber Cancer Institute, he joined the faculty at the Dana-Farber Cancer Institute. He has since been a visiting professor at the University of Pittsburgh School of Medicine, UCLA, the Brin Professor at Johns Hopkins Medical School, and the Kovitz Professor at Stanford Medical School and visiting professor at New York University Law School. Dr. Emanuel has written and edited 9 books and over 200 scientific articles. He is currently a columnist for the New York Times.

https://hcmg.wharton.upenn.edu/profile/1749/

-------------------------------------------------------------

Lets just hope someone like him is on the side of the very latest scientific advances such as the discovery of PS as a biomarket on all solid tumors -- by the late Dr. Philip Thorpe and Peregrine Pharmaceuticals. As an oncologist ( Dr. Ezekial Emanuel )--- breast cancer..etc, I'm sure he would want what patients deserve best and thats the full "immuno-therapy" that only "PS targeting" agents such as Bavituximab can provide. I think he was on some meetings before with Dr. Kurilla before as well..